文献速递肾小球疾病

Povetacicept治疗IgA肾病与原发膜性肾病

Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2025-11-03

这项1/2期开放标签研究评估povetacicept在成人IgA肾病(IgAN)或原发膜性肾病(pMN)患者中的安全性与疗效。IgAN患者80mg组48周时24小时UPCR平均下降64%,eGFR稳定,约90%血尿缓解;pMN患者UPCR平均下降82%,eGFR稳定。药物总体安全耐受。

要点

  • IgAN患者80mg组48周UPCR平均下降64%,65%患者UPCR<0.5g/g。
  • pMN患者UPCR平均下降82%,100%达到免疫学缓解。
  • povetacicept总体安全且耐受性良好。

核心结论

  • povetacicept在IgAN中显著且持续降低UPCR,eGFR稳定,Gd-IgA1显著下降,血尿缓解并达到临床缓解,安全性良好;pMN中观察到类似结果。

研究设计与样本

  • 1/2期开放标签研究,纳入54例IgAN(21例80mg,33例240mg)和10例pMN(均80mg)成人患者,eGFR≥30 ml/min/1.73 m2,每4周皮下给药。

主要发现

  • IgAN 80mg组48周24小时UPCR平均下降64%(95%CI:-76至-48),从1.3 g/g降至0.5 g/g,65%患者UPCR<0.5 g/g,eGFR稳定。
  • IgAN 80mg组Gd-IgA1第12周下降57%,第48周下降77%;约90%血尿缓解,53%达到临床缓解;240mg疗效相似。
  • pMN患者48周24小时UPCR平均下降82%(95%CI:-92至-60),从3.8 g/g降至0.7 g/g,eGFR稳定;aPLA2R第12周下降73%,第48周下降83%,100%免疫学缓解,40%完全缓解,100%部分缓解。

临床怎么用

  • 对于IgAN和pMN患者,povetacicept每4周皮下注射可显著降低蛋白尿并稳定肾功能,同时改善Gd-IgA1或aPLA2R等致病性指标。

局限性

  • 本研究为开放标签、非对照设计,样本量较小(IgAN 54例,pMN 10例),结果需更大规模随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Povetacicept is an inhibitor of B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), 2 cytokines central to the pathogenesis of autoimmune glomerulonephritis. Both BAFF and APRIL promote B-cell and plasma cell survival and function. APRIL primarily supports plasma cell survival and function, whereas BAFF regulates early pathogenic B-cell development, activates pathogenic T cells and innate immune cells, and contributes to mesangial cell proliferation and podocyte injury. METHODS: Our phase 1 and 2, open-label study evaluated povetacicept in adult participants with IgA nephropathy (IgAN) or primary membranous nephropathy (pMN), all with estimated glomerular filtration rate (eGFR) of ≥ 30 ml/min per 1.73 m2. The primary objective was safety. Secondary objectives included change from baseline in urine protein-to-creatinine ratio (UPCR), eGFR, galactose-deficient IgA1 (Gd-IgA1) (IgAN), antiphospholipase A2 receptor autoantibody (aPLA2R; pMN), and clinical remission (with hematuria resolution for IgAN). RESULTS: Povetacicept was administered subcutaneously every 4 weeks (Q4W) to 54 participants with IgAN (21 received 80 mg, 33 received 240 mg) and 10 with pMN (all received 80 mg). In this interim analysis, participants with IgAN on 80 mg had a 64% mean 24-hour UPCR decrease (95% confidence interval: -76 to -48) from baseline (1.3 g/g to 0.5 g/g; 65% with UPCR < 0.5 g/g) with stable eGFR at week 48. Early decline in Gd-IgA1 at week 12 (57%), continued at week 48 (77%). Approximately 90% achieved hematuria resolution and 53% achieved clinical remission. Efficacy outcomes were similar with 240 mg povetacicept. Participants with pMN had an 82% mean 24-hour UPCR decrease (95% confidence interval: -92 to -60) from baseline (3.8 g/g to 0.7 g/g) with stable eGFR. Early decline in aPLA2R at week 12 (73%), continued at week 48 (83%) with 100% in immunologic remission (40% achieved complete remission; 100% achieved partial remission). Povetacicept was generally safe and well-tolerated for IgAN and pMN. CONCLUSION: Povetacicept had substantial, sustained UPCR reductions with stable eGFR, significant Gd-IgA1 reductions, hematuria resolution, clinical remission, with favorable safety in IgAN. Similar results were observed in pMN. By inhibiting both BAFF and APRIL, povetacicept targets the underlying cause of disease and has potential to provide a significant therapeutic advancement for autoimmune glomerular diseases.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Madan A, Yalavarthy R, Kim DK, et al. Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy. Kidney Int Rep. 2025. PMID: 41541780. doi:10.1016/j.ekir.2025.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。